Tuesday, 17 Sep 2019

You are here

Shingles Vaccine Not Cost-Effective in Those Under 60

The herpes zoster (HZ- shingles) vaccine was FDA approved for use in individuals over age 50 years.  However, the CDC Advisory Committee on Immunization Practices (ACIP) has recommended it only be used in those over age 60 years.  

Annals of Internal Medicine reports an a cost-effectiveness analysis of of HZ vaccine versus no vaccination. For every 1000 persons receiving the vaccine at age 50 years, 25 HZ cases and 1 post-herpetic neuralgia case could be prevented. The incremental cost-effectiveness ratio (ICER) for HZ vaccine versus no vaccine was $323 456 per quality-adjusted life-year (QALY).  Typically, preventive treatments are considered cost-effective when they cost at most $100,000 per QALY, that is, per year of healthy life gained.

The HZ vaccine costs over $200. To be cost effective in the 50-59 yr age group the cost would have to be less than $80.  These findings support the ACIP recommendations to limit the vaccine to those over 60 yrs of age.

Le P, Rothberg JB. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years. Ann Int Med Sept 2015

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. 

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.